Compare Meta Platforms Inc (META) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs TG Therapeutics Inc — how do they compare? Meta Platforms Inc trades at $718.67 (market cap $1.84T), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Meta Platforms Inc is far larger — about 225.5× TG Therapeutics Inc's market cap, and Meta Platforms Inc pays a 0.29% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and TG Therapeutics Inc for 16 Days on average.
| META | TGTX | |
|---|---|---|
Market Cap | $1.84T | $8.16B |
Volume | 15,887,049 | 1,735,121 |
Sector | Media | Health |
52-Week High | $777.59 | $59.06 |
52-Week Low | $525.72 | $26.94 |
Typical Hold Time | 127 Days | 16 Days |
Enterprise Value | $1.86T | $8.37B |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $720.89, down 0.06% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with $201B revenue in 2025 and 29.84% net income margin, though Q2 2026 earnings missed expectations. Recent AI developments including the Muse Spark launch and a $21B CoreWeave deal highlight strategic positioning in artificial intelligence infrastructure.
Wall Street maintains strong bullish sentiment with 80% buy ratings and $781 consensus price target, representing 8% upside. Key risks include ongoing youth addiction litigation in Massachusetts and elevated capital expenditures for AI infrastructure. The stock presents growth potential through AI monetization but faces regulatory and execution challenges.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
